In a bold move to reduce U.S. prescription drug prices, AstraZeneca and Pfizer have struck deals with the White House, promising significant discounts for patients. This comes amid rising pressure from President Trump on drugmakers to lower costs or face hefty tariffs. Will these changes truly benefit American patients?
Pfizer's unexpected deal with the Trump administration on drug pricing sends shockwaves through the pharmaceutical industry, pressuring competitors to follow suit amidst potential regulatory threats. What’s next for drug prices?
Eli Lilly announces a dramatic price increase for its diabetes medication Mounjaro in the UK, raising the monthly cost from £122 to £330. This change affects private buyers but not NHS prescriptions. Learn more about the implications!
In a surprising move, Lars Fruergaard Jørgensen is stepping down as CEO of Novo Nordisk after years of leading the company through a successful phase in obesity and diabetes medications. As the search for his successor begins, what does this mean for the future of the pharmaceutical giant?
In a landmark move, President Trump signs an Executive Order aimed at reducing prescription drug prices for Americans, aligning them with those in other wealthy nations. This initiative seeks to curb unfair pricing practices and ensure a fair deal for U.S. patients.
President Trump signs an executive order reviving the 'most favored nation' policy to slash drug costs by linking U.S. prices to lower prices abroad. Will this finally bring relief to American patients?
President Trump is set to sign an executive order aiming to lower drug prices in the US by aligning them with prices in wealthy nations. This 'most favored nation' model could face legal challenges.
Casey Means, a controversial figure in the health sector, faces backlash from MAGA influencers and former allies as she advocates for lifestyle changes to prevent chronic diseases. Discover the tensions surrounding her nomination and her views on vaccines.
In a pivotal court ruling, Judge Mark Pittman denied compounding pharmacies' request for an injunction against the FDA's decision on the semaglutide shortage. This ruling keeps strict timelines for exiting the market, leaving many in the industry concerned.
As President Trump prepares to unveil a major tariff plan, pharmaceutical companies are lobbying for a gradual implementation to mitigate the impact on drug prices and supply. With potential tariffs looming, how will the industry adapt?
